Key result
Surgical resection plus weekly adjuvant paclitaxel yields disease-free survival at 36 months in case report.
Why the study?
Pulmonary artery intimal sarcoma is a rare disease with dismal prognosis and unestablished standard therapies, where the survival benefit of adjuvant chemotherapy remains without consensus.
Does surgical resection followed by weekly paclitaxel therapy improve survival in patients with pulmonary artery intimal sarcoma?
Case Report (n=1)
No
Does surgical resection followed by weekly paclitaxel therapy improve survival in patients with pulmonary artery intimal sarcoma?
Weekly paclitaxel administration following surgical resection may be a feasible adjuvant treatment option for pulmonary artery intimal sarcoma.
May support weekly paclitaxel after resection in pulmonary artery intimal sarcoma; leaves open prospective validation.
IntroductionPulmonary artery intimal sarcoma (PAIS) is a rare disease with a probably underestimated incidence at 0.001%–0.03% because it frequently mimics pulmonary vascular diseases, including acute pulmonary embolism 1-3. The literature reported only a few hundred PAIS cases, most of which were published as case reports4, 5. The mean age at diagnosis is 50 years and the range of age is estimated as 13–86 years 5. Several studies indicate the dismal prognosis of PAIS, especially among patients with delayed diagnosis 4-6. Standard therapies remain unestablished, but surgical resection is still the mainstay of treatment5. The effect of adjuvant chemotherapy and radiotherapy on the overall survival rate of patients has no consensus. However, the addition of chemotherapy and radiotherapy postoperatively may improve the outcome of patients with PAIS 6. Here, we report a 53-year-old female patient with PAIS who was successfully treated with surgery followed by weekly paclitaxel therapy.
No takes yet. Share an insight, caveat, or question.
Endo et al. (2026) conducted a case report in Pulmonary artery intimal sarcoma (PAIS) (n=1). Surgical resection followed by weekly paclitaxel therapy was evaluated on Disease-free survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: